Neural Noise

Transcranial brain stimulation for addiction

2 min read

  • Transcranial stimulation is being explored as an emerging therapeutic application for addiction (YaleNews).1
  • The approach fits within the tDCS/tACS neuromodulation narrative for clinical translation.1 1

Gardner updates

  • Transcranial stimulation is an emerging therapeutic application for addiction (YaleNews) . 1

  • Brain stimulation may reduce cannabis addiction in people with multiple sclerosis (NYU Langone; transcranial stimulation in neurological populations). 2

  • tDCS restores addictive behavior via prefrontal-striatal circuit mechanisms (Molecular Psychiatry). 3

Weekly enrichment (2026-07-20)

  • A Yale-sponsored Phase 1 trial (NCT01567982, 60 participants) tested tDCS at 2 mA for 20 minutes over prefrontal and/or parietal cortex to reduce tobacco withdrawal in smokers abstinent for more than 10 hours.4
  • In a within-subject, sham-controlled study of 24 overnight-abstinent smokers, anodal tDCS to the left dorsolateral prefrontal cortex (dlPFC; cathode over the right supra-orbital area, 2.0 mA, 20 min) significantly reduced negative affect (POMS tension-anxiety, depression, confusion) but did not reduce cigarette craving versus sham.5
  • The mood benefit correlated with nicotine-dependence severity (Fagerström), and no significant tDCS side effects were reported, supporting the technique’s safety.5
  • A Yale randomized trial in 33 men with internet gaming disorder found active right-dlPFC tDCS (1.5 mA, 20 min) enhanced regulation of both craving and negative emotions versus sham — reported as the first experimental evidence for a shared right-dlPFC role across two addiction drivers.6
  • A pilot RCT for cannabis use disorder pairs 1.5 mA anodal tDCS over the right dlPFC (5 weekly 20-minute sessions) with cognitive-reappraisal training in 60 participants randomized to active versus sham.7
  • A placebo-controlled crack-cocaine trial (17 active versus 19 sham) using repetitive bilateral dlPFC tDCS reported reduced craving, decreased anxiety, and improved quality of life in the active group.8
  • A 2018 review synthesized 60 studies (2000–2017) of rTMS, tDCS, and DBS across tobacco, alcohol, cannabis, opioids, and stimulants; tDCS for addiction is currently rated “Level B” (probably effective) evidence.8
  • Across trials the dlPFC is the consistent target, reflecting its role in executive/inhibitory control over substance-related decision-making; craving results remain mixed, so tDCS stays an experimental adjunct often combined with behavioral tasks such as reappraisal training.5 7

Footnotes

  1. https://news.google.com/rss/articles/CBMieEFVX3lxTE1STldFRnFXcTNCTllPSzYtUk5obGZMX3BpV001NURsbEtpWU5meWpjaEZPT3FVVzF0ZkJ2U0pTVEJZTjUteksxZ3AyZXVUTXpOb0lGYXkzU1NqRDExTTJwTmc1S1BfUHdVNE56ZFFOXzJ1YmRiRDMyag?oc=5 ↩ ↩2 ↩3 ↩4

  2. https://news.google.com/rss/articles/CBMiowFBVV95cUxOTjNXSWtyeWM2bjdlX1Btd21TblBFZGFxMGJabmVvSC1YRjByNTRRZjNtNVlqWjI4SWxiQzdJVFNBd0NRU3hyREtUcHlWRXEyUm5CSUk1TWdvNGRCMlpySXdrMnNsMjJwZU54RUkyRURRdVQ2TDE5VVFiSG5NYXVwRHVudmtLQWlkZGh0WldzblExWjFyai1RbXFNVWFTME5Rd1Br?oc=5 ↩

  3. https://news.google.com/rss/articles/CBMiX0FVX3lxTE54aDduVXlJVzVqU19IUHNmcGxSMkxIbk1BbnJNNjRpMnctWk1tSldNc0V2UWlJX0JER3hTbkNuQjNkaFQ2MDNmZ3ZmLWtveDZzSFBiYUp3cldDcFVuYzdN?oc=5 ↩

  4. https://clinicaltrials.gov/study/NCT01567982 ↩

  5. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2013.00112/full ↩ ↩2 ↩3

  6. https://canlab.yale.edu/sites/default/files/Wu_et_al_2020_Role_for_the_right_dlpfc_in_enhancing_regulation_of_craving_and_negative_emotions.pdf ↩

  7. https://doi.org/10.1371/journal.pone.0328205 ↩ ↩2

  8. https://www.neurocaregroup.com/tdcs-for-addiction-addictive-disorders ↩ ↩2

Graph View